Sanofi (NYSE:SNY)‘s stock had its “buy” rating reiterated by analysts at Deutsche Bank in a report released on Monday.
A number of other research firms have also weighed in on SNY. UBS reissued a “neutral” rating on shares of Sanofi in a report on Monday, January 15th. ValuEngine lowered Sanofi from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. JPMorgan Chase reissued a “neutral” rating on shares of Sanofi in a report on Thursday, January 11th. Barclays lowered Sanofi from an “equal weight” rating to an “underweight” rating in a report on Tuesday, January 23rd. Finally, Cowen set a $48.00 target price on Sanofi and gave the stock a “hold” rating in a report on Monday, December 18th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the stock. Sanofi has a consensus rating of “Hold” and an average price target of $49.33.
NYSE:SNY opened at $40.56 on Monday. The company has a market cap of $101,728.05, a price-to-earnings ratio of 12.96, a P/E/G ratio of 2.06 and a beta of 0.85. Sanofi has a twelve month low of $38.14 and a twelve month high of $50.65. The company has a current ratio of 1.70, a quick ratio of 1.26 and a debt-to-equity ratio of 0.25.
Sanofi (NYSE:SNY) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $0.62 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.07). The company had revenue of $8.69 billion for the quarter, compared to analyst estimates of $8.65 billion. Sanofi had a return on equity of 24.30% and a net margin of 23.25%. The firm’s revenue for the quarter was down 2.1% compared to the same quarter last year. During the same period last year, the firm earned $1.25 EPS. research analysts forecast that Sanofi will post 3.35 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNY. Deutsche Bank AG boosted its stake in Sanofi by 369.7% in the 4th quarter. Deutsche Bank AG now owns 1,462,947 shares of the company’s stock valued at $62,903,000 after purchasing an additional 1,151,455 shares during the period. Fisher Asset Management LLC boosted its stake in Sanofi by 3.0% in the 4th quarter. Fisher Asset Management LLC now owns 14,500,758 shares of the company’s stock valued at $623,533,000 after purchasing an additional 418,501 shares during the period. Senzar Asset Management LLC boosted its stake in Sanofi by 25.4% in the 4th quarter. Senzar Asset Management LLC now owns 999,786 shares of the company’s stock valued at $42,990,000 after purchasing an additional 202,300 shares during the period. OLD Mission Capital LLC boosted its stake in Sanofi by 250.4% in the 4th quarter. OLD Mission Capital LLC now owns 280,376 shares of the company’s stock valued at $12,056,000 after purchasing an additional 200,355 shares during the period. Finally, Southpoint Capital Advisors LP boosted its stake in Sanofi by 10.0% in the 4th quarter. Southpoint Capital Advisors LP now owns 2,200,000 shares of the company’s stock valued at $94,600,000 after purchasing an additional 200,000 shares during the period. Institutional investors and hedge funds own 8.98% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Sanofi (SNY) Stock Rating Reaffirmed by Deutsche Bank” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at www.tickerreport.com/banking-finance/3361890/sanofi-sny-stock-rating-reaffirmed-by-deutsche-bank.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.